# Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection

> **NCT00885820** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 240 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** MMF
- **DRUG:** Corticosteroids (Prednisone)

## Key facts

- **NCT ID:** NCT00885820
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2004-07
- **Final completion:** 2006-01
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2014-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00885820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00885820, "Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00885820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*